|Corresponding Author: Tetsuro Tamaki, Ph.D, Muscle Physiology and Cell Biology Unit, Department of Human structure and Function, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan, Tel: +81-463-93-1121 (ext.2524); Fax: +81+463-95-0961; E-mail: firstname.lastname@example.org|
|Received: November 3, 2015; Accepted: November 30, 2015; Published: July 25, 2016;|
|Citation: Tamaki T. (2016) Paracrine Effect of Skeletal Muscle-Derived Stem Cell Transplantation: The Case of Peripheral Nerve Long-Gap Injury Therapy. Stem Cell Res Th, 1(1): 1-5.|
|Copyrights: ©2016 Tamaki T. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
The possibility and importance of paracrine effect of stem cell transplantation were discussed in this commentary. Although the primary purpose of stem cell transplantation therapy is absolutely the differentiation and incorporation of engrafted cells to facilitate the target tissue reconstitution. However, the paracrine effects surrounding recipient cells and/or donor cells each other is also a reasonable issue. We have experienced a typical case of paracrine effect in the experimental therapy of peripheral nerve injury using skeletal muscle-derived stem cells (Sk-SCs). The severe nerve injury with long-gap was made in the mouse and rat sciatic nerve, and bridged by a cellular conduit. The mouse Sk-CSs and bone marrow stromal cells (BMSCs) were obtained from GFP-Tg mice, and transplanted into the conduit. After 8-weeks, transplanted Sk-SCs differentiated into all the peripheral nerve support cells (such as Schwann, endoneurial/perineurial cells), and contributed to the recovery of the number of axon for almost 90% and close to 60% of myelin following significant functional recoveries. In contrast, BMSCs group showed the results similar to the non-cell transplanted control, and cells were eliminated during the first week. On the other hand, we also found that the human Sk-SCs, sorted as CD34+/45- (Sk-34) cells, showed wholly comparable results of the mouse (such as cell engraftment, differentiation, and recoveries of axon/myelin, and functions)after 12-weeks of transplantation. However, the human CD34-/45-/29+ (Sk-DN) cells, which was composed mostly skeletal-myogenic cells, showed no engraftment in the nerve tissue, but remained during 4 weeks, and showed significantly higher numerical and functional recoveries than the control, while these were clearly lower than Sk-34. This result suggested two important points; 1)the skeletal-myogenic cells are not able to grow and differentiate in the peripheral nerve specific niche, but 2) they accelerate nerve recovery, probably their paracrine effects. It is likely that during 4-weeks of cell survival with paracrine after transplantation is a sufficient condition, but one-week is insufficient.
Recently, we experienced the certain case of the paracrine effects in the experimental therapies of the severely damaged peripheral nerve with a log-gap, using mouse and human skeletal muscle-derived stem cells (Sk-SCs). Because of this background, the paracrine effects of these cells before and after transplantation are discussed in this commentary, with the comparison with the case of bone-marrow-derived stromal cells (BMSCs).
Loss of vital functions in the somatic motor and sensory nervous systems can be induced by severe peripheral nerve transection with a long gap following trauma. In such cases, autologous nerve grafts have been used as the gold standard, with the expectation of activation and proliferation of graft-concomitant Schwann cells associated with their paracrine effects. However, there are a limited number of suitable sites available for harvesting of nerve autografts due to the unavoidable sacrifice of other healthy functions. To overcome this problem, we examined the potential of Sk-SCsas a novel alternative cell source for peripheral nervere generation therapy [1,2].The reason is that the Sk-SCs including CD34+/45- (Sk-34)  and CD34-/45- (Sk-DN)  cells, which showed differentiation potential into mesodermal cells (skeletal muscle cells, vascular smooth muscle cells, pericytes and endothelial cells) and ectodermal cells (Schwann cells and perineurial cells) in vivo, and typically exerted synchronized reconstitution of the muscular, vascular and peripheral nervous system in the severely damaged skeletal muscle[5-7]. The potential was not changed, when both Sk-34 and Sk-DN cells were used by the mixed cells, as the Sk-SCs [8-10]. Because of this background, we made sciatic nerve long-gap transection model of mice (7-mm) and rats (12-mm), and bridged using anacellular conduit made from separated esophageal submucous membrane from mice after 3-days of 70% ethanol treatment. Then, the cells were injected in the bridging-conduit . As we expected in the mouse-to-mouse experiment, the transplanted Sk-SCs differentiated into all the peripheral nerve support cells(such as Schwann, endoneurial/perineurial cells), and contributed to the recovery of the number of axon for almost 90% and close to 60% of myelin (Figure 1A and 1B). Interestingly, myogenic cells were also observed in this nerve niche, but the skeletal myogenic capacity of expanded Sk-SCs had been diminished gradually, and completely disappeared at 4-weeks after the transplantation . Similarly, BMSCs transplantation was also performed, however, the results showed almost no effects (wholly comparable to the level of medium control) for the recoveries of the number of axons and myelin (Figure 1A and B). In addition, transplanted BMSCs disappeared during first one week. Therefore, no cell engraftment with no effect is reasonable in this case.
We also established the appropriate isolation and expansion culture method for the humanSk-34 and Sk-DN cells, and transplanted them into the sever muscle injury model of nude mouse and rat . Then, we found that the combined results of both cell transplantation showed wholly comparable differentiation capacities of the mouse Sk-SCs . However, very interestingly, the human Sk-DN fraction showed the limited inclusion of the skeletal-myogenic cells, whereas, the other multipotent stem cells were contained in the Sk-34 fraction . Therefore, we applied human Sk-34 and Sk-DN cells to the nerve-gap model separately, because the elimination of skeletal-myogenic cells have been already confirmed in the previous mouse Sk-SCs experiment .As expected, the human Sk-34 cells showed cellular differentiations comparable to the mouse Sk-SCs (data not shown), with favorable recovery of the number of axons and myelin (Figure 2A and 2B), and the contractile functions of downstream muscles (Figure 2C) at 12-weeks after transplantation. More interestingly, human Sk-DN cells (skeletal myogenic cell dominant population) were also eliminated similar to the above case of BMSCs, but the term took 4-weeks after transplantation. A similar elimination of skeletal-myogenic cells in the nerve niche were also confirmed in the previous mouse Sk-SCs during 4-weeks after transplantation .Thus, it is certain that the skeletal-myogenic cell is not able to growth and differentiates in the peripheral nerve specific niche. In contrast, it is also clear that the Sk-DN cells remained during 4-weeks after transplantation, whereas the BMSCs was eliminated within one-week. In addition, the human Sk-DN group showed significantly higher regenerations than that of the medium control at 12-weeks after transplantation, while the levels are apparently lower than the Sk-34 group (Figure 2A, 2B and 2C).
differences in both groups are considered due to the prolonged survival/engraftment/paracrine
of Sk-34 cells and their differentiation into all the nerve support cells.
However, it is also certain that the complete elimination of the human Sk-DN
cells occurred during 4-weeks after transplantation, but significantly higher
morphological and functional recoveries than the control was achieved.
Therefore, this is reasonable to consider that this result may be due to the
paracrine effects of human Sk-DN cells during 4-weeks after transplantation.
Putative paracrine capacities of human Sk-34 and Sk-DN cells, which was
supposed by expressions of mRNAs were shown in Figure 3. Both cells consistently expressed 8 analyzed nerves and 5
analyzed vascular growth factors just before the transplantation, and a
comparable paracrine effect can be expected. In fact, these expressions of
mRNAs have wholly kept in the Sk-34 cells even at 4-weeks after
transplantation; this was confirmed by the analysis for the engrafted Sk-34
cells, which was re-isolated enzymatically, and sorted using human-specific
antibody (data not shown). In the comparison of the above mouse and human cell
studies, both the mouse BMSCs and the human Sk-DN cells were eliminated in the
peripheral nerve niche, but the former showed no effects for nerve regeneration,
and the latter showed a significant contribution for the recovery. What makes a
difference between them; that is the term of elimination, thus how long stay in
the damaged tissue is considered to be the limiting factor of the paracrine
effects following stem cell transplantation, because the expressions of
nerve-vascular growth factor mRNAs were similar in both the mouse BMSCs  and
present human Sk-DN cells (Figure 3)
at just before the transplantation. In these view points, it is likely that one
week of the cell retaining-period is insufficient, but 4-weeks retaining, with
continuous expressions of growth factors after the onset of the damage, may
have a beneficial effect on the nerve regeneration. However, we still not
perform a more quantitative analysis (such as real-time RT-PCR) for the
expressions of nerve-vascular growth factors in Sk-34 and Sk-DN cells.
Therefore, further experiments, to clarify which factors may play a more
prominent paracrine role during regeneration process, should be necessary.
From the other point of view, it was also suggested that the paracrine substances of skeletal-myogenic cells exert facilitative effects for the peripheral nerve regeneration process. This concept further suggests that the skeletal muscle fiber and peripheral nerve regeneration process may share the large number of essential factors, and they co-working together. This notion also supports the previous results of Sk-SCs transplantation that asynchronized reconstitution of muscle-nerve-blood vessels were induced in the severe muscle injury with a sizable defect [5,6].
Finally, the cytokine supply associate with the stem cell transplantation was proposed in this commentary. However, administration therapy of recombinant cytokines, which will be selected appropriately in the near future, should be also considered. In particular, the nerve injury categorized in the Seddons’s axonotmesis and/or the Sunderland’s fourth degree, because the continuity of the epineurium (the most outer layer) is maintained, but involves loss of axons, endoneurial tubes, perineurial fasciculi and vascular networks, thus, associated with a bad prognosis. In addition, a development of the nerve bridging materials, which enable a sustained-release of cytokines, such as the biodegradable tubes, is also much-needed.
Through these studies, it is supposed that the
first 2-3 weeks from the onset of nerve damage may be a critical period to
supply nerve-vascular growth factors to obtain the better nerve regeneration.
This notion is found to be useful for future cytokine therapy for the severe
peripheral nerve injury.
- Tamaki T (2014) Bridging long gap peripheral nerve injury using skeletal muscle-derived multipotent stem cells. Neural Regen Res 9: 1333-1336.
- Tamaki T, Hirata M, Soeda S, Nakajima N, Saito K, et al. (2014) Preferential and comprehensive reconstitution of severely damaged sciatic nerve using murine skeletal muscle-derived multipotent stem cells. PLoS One 9: e91257.
- Tamaki T, Akatsuka A, Ando K, Nakamura Y, Matsuzawa H, et al. (2002). Identification of myogenic-endothelial progenitor cells in the interstitial spaces of skeletal muscle. J Cell Biol 157: 571-577.
- Tamaki T, Akatsuka A, Okada Y, Uchiyama Y, Tono K, et al. (2008) Cardiomyocyte formation by skeletal muscle-derived multi-myogenic stem cells after transplantation into infarcted myocardium. PLoS ONE 3: e1789.
- Tamaki T, Uchiyama Y, Okada Y, Ishikawa T, Sato M, et al. (2005) Functional recovery of damaged skeletal muscle through synchronized vasculogenesis, myogenesis, and neurogenesis by muscle-derived stem cells. Circulation 112: 2857-2866.
- Tamaki T, Okada Y, Uchiyama Y, Tono K, Masuda M, et al. (2007) Synchronized reconstitution of muscle fibers, peripheral nerves and blood vessels by murine skeletal muscle-derived CD34(-)/45 (-) cells. Histochem Cell Biol 128: 349-360.
- Tamaki T, Okada Y, Uchiyama Y, Tono K, Masuda M, et al. (2007) Clonal multipotency of skeletal muscle-derived stem cells between mesodermal and ectodermal lineage. Stem Cells 25: 2283-2290.
- Saito K, Tamaki T, Hirata M, Hashimoto H, Nakazato K, et al. (2015) Reconstruction of Multiple Facial Nerve Branches Using Skeletal Muscle-Derived Multipotent Stem Cell Sheet-Pellet Transplantation. PLoS One 10: e0138371.
- Soeda S, Tamaki T, Hashimoto H, Saito K, Sakai A, et al. (2013) Functional Nerve-Vascular Reconstitution of the Bladder-Wall; Application of Patch Transplantation of Skeletal Muscle-Derived Multipotent Stem Cell Sheet-Pellets. J Stem Cell Res Ther 3: 142.
- Tamaki T, Soeda S, Hashimoto H, Saito K, Sakai A, et al. (2013) 3D reconstitution of nerve-blood vessel networks using skeletal muscle-derived multipotent stem cell sheet pellets. Regen Med 8: 437-451.
- Tamaki T, Uchiyama Y, Hirata M, Hashimoto H, Nakajima N, et al. (2015) Therapeutic isolation and expansion of human skeletal muscle-derived stem cells for the use of muscle-nerve-blood vessel reconstitution. Front Physiol 6: 165.
- Okabe M, Ikawa M, Kominami K, Nakanishi T, Nishimune Y (1997) 'Green mice' as a source of ubiquitous green cells. FEBS Lett 407: 313-319.